[
  {
    "ts": null,
    "headline": "Here Are the 12 Best ‘Buyback Aristocrat’ Stocks",
    "summary": "The average Dividend Aristocrat has barely managed a positive return over the past 12 months. The average Buyback Aristocrat has returned about 17%.",
    "url": "https://finnhub.io/api/news?id=573b6d98c561d45dc5a84a6b456d5eafb84db9531e3b10c5d8147b8a72944744",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759954740,
      "headline": "Here Are the 12 Best ‘Buyback Aristocrat’ Stocks",
      "id": 137027413,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The average Dividend Aristocrat has barely managed a positive return over the past 12 months. The average Buyback Aristocrat has returned about 17%.",
      "url": "https://finnhub.io/api/news?id=573b6d98c561d45dc5a84a6b456d5eafb84db9531e3b10c5d8147b8a72944744"
    }
  },
  {
    "ts": null,
    "headline": "Finally, Tariffs the Stock Market Likes. Why Pharma Levies May Do the Trick.",
    "summary": "Unlike the broad reciprocal tariffs announced on April 2, which triggered a market crash, Trump’s new drug tariffs, announced in conjunction with a new government-run drug sales platform last month, seems to have boosted investor confidence.  Stocks of major pharmaceutical firms, including  Eli Lilly GSK Merck Novartis Johnson & Johnson  and  Pfizer rose.  The market’s reaction suggests enthusiasm for the administration’s multifaceted strategy to overhaul the pharmaceutical industry.",
    "url": "https://finnhub.io/api/news?id=fde8b62877dcbe4bf2b03b87a111b78c324445ab22863a4ab7e9d31e5ca48347",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759949280,
      "headline": "Finally, Tariffs the Stock Market Likes. Why Pharma Levies May Do the Trick.",
      "id": 137028255,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Unlike the broad reciprocal tariffs announced on April 2, which triggered a market crash, Trump’s new drug tariffs, announced in conjunction with a new government-run drug sales platform last month, seems to have boosted investor confidence.  Stocks of major pharmaceutical firms, including  Eli Lilly GSK Merck Novartis Johnson & Johnson  and  Pfizer rose.  The market’s reaction suggests enthusiasm for the administration’s multifaceted strategy to overhaul the pharmaceutical industry.",
      "url": "https://finnhub.io/api/news?id=fde8b62877dcbe4bf2b03b87a111b78c324445ab22863a4ab7e9d31e5ca48347"
    }
  },
  {
    "ts": null,
    "headline": "Nuvation Bio Inc. (NUVB): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Nuvation Bio Inc. on wallstreetbets subreddit by asagi_lumina. In this article, we will summarize the bulls’ thesis on NUVB. Nuvation Bio Inc.’s share was trading at $3.2200 as of September 23rd. Nuvation Bio (NUVB), founded in 2018 by David T. Hung, M.D., is an oncology biotech focused on next-generation kinase […]",
    "url": "https://finnhub.io/api/news?id=cf7dd73241cc1de75c84775d1194cc4e19992e5bbfffa2ee33e46dcb352dfe20",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759942965,
      "headline": "Nuvation Bio Inc. (NUVB): A Bull Case Theory",
      "id": 137013037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Nuvation Bio Inc. on wallstreetbets subreddit by asagi_lumina. In this article, we will summarize the bulls’ thesis on NUVB. Nuvation Bio Inc.’s share was trading at $3.2200 as of September 23rd. Nuvation Bio (NUVB), founded in 2018 by David T. Hung, M.D., is an oncology biotech focused on next-generation kinase […]",
      "url": "https://finnhub.io/api/news?id=cf7dd73241cc1de75c84775d1194cc4e19992e5bbfffa2ee33e46dcb352dfe20"
    }
  },
  {
    "ts": null,
    "headline": "Sizing Up Pfizer After Drug Pricing Deal Finalized With Trump Administration",
    "summary": "If you are watching Pfizer right now and feeling uncertain about whether to stay, buy, or even take profits, you are definitely not alone. Over the last month, Pfizer’s stock has climbed 5.6%, including a recent 3.1% push in just a week. But this rebound is set against a much tougher long-term backdrop, with shares still down 1.3% year-to-date and off 3.7% over the past year. The bigger picture shows a longer slide of 26.1% in three years and nearly 5% in five years. Clearly, investors have...",
    "url": "https://finnhub.io/api/news?id=58299def87d3814309221352b74d1a34f933eb35a7baea55ba8f1482fd08ffa4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759939843,
      "headline": "Sizing Up Pfizer After Drug Pricing Deal Finalized With Trump Administration",
      "id": 137013038,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you are watching Pfizer right now and feeling uncertain about whether to stay, buy, or even take profits, you are definitely not alone. Over the last month, Pfizer’s stock has climbed 5.6%, including a recent 3.1% push in just a week. But this rebound is set against a much tougher long-term backdrop, with shares still down 1.3% year-to-date and off 3.7% over the past year. The bigger picture shows a longer slide of 26.1% in three years and nearly 5% in five years. Clearly, investors have...",
      "url": "https://finnhub.io/api/news?id=58299def87d3814309221352b74d1a34f933eb35a7baea55ba8f1482fd08ffa4"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Pfizer (PFE) Before a Breakout Begins?",
    "summary": "We recently published Top 10 Trending Stocks as Famous Billionaire Predicts Massive AI Stock Rally Before Bubble Burst. Pfizer Inc (NYSE:PFE) is one of the trending stocks. Analysts are getting excited about major healthcare stocks like Pfizer and expect a rally in the sector to begin soon. Evan Seigerman, head of healthcare research at BMO […]",
    "url": "https://finnhub.io/api/news?id=e2b0cd8781c60fcbc144f19ce83b748d7a9fd0fb2f36311cc1124b064d88d633",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759937315,
      "headline": "Should You Buy Pfizer (PFE) Before a Breakout Begins?",
      "id": 137011683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published Top 10 Trending Stocks as Famous Billionaire Predicts Massive AI Stock Rally Before Bubble Burst. Pfizer Inc (NYSE:PFE) is one of the trending stocks. Analysts are getting excited about major healthcare stocks like Pfizer and expect a rally in the sector to begin soon. Evan Seigerman, head of healthcare research at BMO […]",
      "url": "https://finnhub.io/api/news?id=e2b0cd8781c60fcbc144f19ce83b748d7a9fd0fb2f36311cc1124b064d88d633"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead",
    "summary": "These biotechs could finally come into their own by the end of the decade.",
    "url": "https://finnhub.io/api/news?id=c91fdae9d3ceeab7873778dcc07b009a75038665e0799c9c774795a78b8b0f33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759932900,
      "headline": "Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead",
      "id": 137011012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These biotechs could finally come into their own by the end of the decade.",
      "url": "https://finnhub.io/api/news?id=c91fdae9d3ceeab7873778dcc07b009a75038665e0799c9c774795a78b8b0f33"
    }
  },
  {
    "ts": null,
    "headline": "Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings",
    "summary": "Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.",
    "url": "https://finnhub.io/api/news?id=4222835e405c672e97b2d5ef9e8bc676ddc39cdc39fdafa5fb4cb7dc23c73cd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759927800,
      "headline": "Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings",
      "id": 137010956,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.",
      "url": "https://finnhub.io/api/news?id=4222835e405c672e97b2d5ef9e8bc676ddc39cdc39fdafa5fb4cb7dc23c73cd8"
    }
  },
  {
    "ts": null,
    "headline": "3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal",
    "summary": "Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.",
    "url": "https://finnhub.io/api/news?id=afaf6649daed343b9252aa5db06d3c24ee53b34e198f1cbee2016a4238baec25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759927320,
      "headline": "3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal",
      "id": 137010911,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.",
      "url": "https://finnhub.io/api/news?id=afaf6649daed343b9252aa5db06d3c24ee53b34e198f1cbee2016a4238baec25"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Mastering The Art Of The Deal With Metsera - Upgraded To Buy",
    "summary": "Pfizer has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Click to read why PFE is a Buy.",
    "url": "https://finnhub.io/api/news?id=16da06b0d07f167a6aaef409dde66b698fedfb114433586ed34032735405c653",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759925884,
      "headline": "Pfizer: Mastering The Art Of The Deal With Metsera - Upgraded To Buy",
      "id": 137011731,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2077560078/image_2077560078.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer has re-entered the obesity drug sector by acquiring Metsera, Inc., having successfully outmaneuvered six other bidders. Click to read why PFE is a Buy.",
      "url": "https://finnhub.io/api/news?id=16da06b0d07f167a6aaef409dde66b698fedfb114433586ed34032735405c653"
    }
  },
  {
    "ts": null,
    "headline": "Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman",
    "summary": "SAN CARLOS, Calif., October 08, 2025--Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman",
    "url": "https://finnhub.io/api/news?id=a9fd62a1b4ca2a30527e726673bbe62f6500643377cd31a96721609132c8e6ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759921200,
      "headline": "Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman",
      "id": 137010135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SAN CARLOS, Calif., October 08, 2025--Mikael Dolsten, M.D., Ph.D., Joins TRIO Pharmaceuticals as Chairman",
      "url": "https://finnhub.io/api/news?id=a9fd62a1b4ca2a30527e726673bbe62f6500643377cd31a96721609132c8e6ca"
    }
  }
]